The 3 most recent market catalysts affecting $LENZ, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 65
Major Shareholder RA Capital Management Sells Shares of LENZ Therapeutics
RA Capital Management, a prominent institutional investor, sold 2,718,700 shares of LENZ Therapeutics common stock for approximately $9.13 million. This divestment by a major share…
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 75
LENZ Therapeutics Reports Q3 2026 Financial Results, Announces Strategic Reorganization and CEO Succession
LENZ Therapeutics announced a strategic reorganization in Q4 2026 to streamline operations and focus on sales. Concurrently, CEO Eef Schimmelpennink will depart on December 1, 2026…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 92
LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate
LENZ Therapeutics announced Q2 results that significantly exceeded analyst expectations. The company reported a loss of $(1.02) per share, beating the $(1.06) estimate, and sales o…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.